Introduction {#Sec1}
============

Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is a valuable tool for obtaining histological diagnoses and has been widely used since it was first reported \[[@CR1]\]. EUS-FNA provides high histological diagnostic accuracy for pancreatic lesions, submucosal tumors, and lymph nodes \[[@CR2]--[@CR10]\]. Although adverse events such as pancreatitis, bleeding, and perforation are known to be associated with EUS-FNA, the reported complication rate is extremely low \[[@CR11]--[@CR16]\]. However, adverse events associated with EUS-FNA have not yet been clearly defined and nor has their severity been classified. Moreover, the risk factors for adverse events associated with EUS-FNA procedures have not yet been determined. The purpose of this study was to determine the incidence of adverse events in patients undergoing EUS-FNA who were registered in our database and to identify risk factors for the development of post-procedural adverse events in patients who undergo FNA of pancreatic solid lesions.

Patients and Methods {#Sec2}
====================

Patients {#Sec3}
--------

A total of 316 consecutive patients with pancreatic solid lesions who underwent 327 EUS-FNA procedures from April 2003 to September 2011 were included in the study (Table [1](#Tab1){ref-type="table"}). We registered all patients undergoing EUS-FNA in the database and retrospectively ascertained the presence/absence of complications. We performed EUS-FNA on pancreatic solid lesions because cystic tumors were a contraindication at our center. Patients with hemorrhagic tendencies were not included as candidates for EUS-FNA, and those on anticoagulant therapy were instructed to discontinue the medication prior to the procedure. Prior to undergoing EUS-FNA, all patients provided written informed consent.Table 1Baseline characteristics of pts who underwent EUS-FNA of pancreatic solid lesionsCharacteristicsValuesAge, years, mean + SD (range)66.5 ± 11.5 (23--92)Sex, M:F178:149Diagnosis Pancreatic cancer275 (84.1 %) Chr. pancreatitis/TFP24 (7.3 %) PNET13 (4.0 %) AIP4 (1.2 %) Metastatic tumor2 (0.6 %) SPN2 (0.6 %) Accessary spleen2 (0.6 %) Others5 (1.5 %)Needle size 19-guage31 (9.5 %) 22-gauge268 (82 %) 25-gauge28 (8.6 %)*TFP* tumor forming pancreatitis, *PNET* pancreatic neuroendocrine tumor, *AIP* autoimmune pancreatitis, *SPN* solid-pseudopapillary neoplasm

EUS-FNA Procedures {#Sec4}
------------------

All patients who were scheduled to undergo FNA were hospitalized for the procedure. EUS-FNA procedures were performed by physicians who perform an average of 150 patients per year and have more than 10 years of experience. Blood analyses were performed less than 48 h before EUS-FNA. All the patients were placed in the left lateral position, and sedation was accomplished using either intravenous diazepam (5 mg) or pethidine hydrochloride (35 mg) along with intravenous midazolam (5 mg). The patients were kept fasting after the procedure and given an antibiotic twice after the examination.

All FNA procedures were completed using a curved linear echo endoscope (GF-UCT240, GF-UCT260; Olympus Medical Systems, Tokyo, Japan). Basically, a 22-G needle (EZ-shot; Olympus Medical Systems; and EchoTip Ultra; Cook Medical, Winston-Salem, NC, USA) was used; however, a 19- or 25-G needle (EchoTip Ultra; Cook Medical) was selected when necessary. Immediately after the tissue samples were obtained, they were stained using the Diff-Quik method in the presence of a cytologist to confirm the adequacy of the sample for cytological diagnosis.

All ultrasonography images obtained during the procedure were stored on a computer as electronic images. Using these images, we retrospectively confirmed whether the needle pass site as via normal pancreatic tissue (Fig. [1](#Fig1){ref-type="fig"}a, b). In cases where the needle pass was via normal pancreatic tissue, the length of the needle penetration was measured (Fig. [1](#Fig1){ref-type="fig"}c). The length was measured using a distance marker on the ultrasonography images and assigned to one of 3 categories: \<1, 1--2, and \>2 cm.Fig. 1Using ultrasound images, needle pass site was confirmed as via normal pancreatic tissue. **a** Needle pass was not via normal pancreas. **b** Needle pass via normal pancreas. **c** In cases where the needle pass was via normal pancreatic tissue, the length of the needle penetration was measured. The length was measured using a distance marker on the ultrasonography images and assigned to one of 3 categories: \<1, 1--2, and \>2 cm

Assessment of Adverse Events and Variables {#Sec5}
------------------------------------------

Physicians and/or nurses confirmed the subjective symptoms and physical findings on the day following the procedure and at least 1 week later. Blood biochemical tests were also performed for all patients to detect any abnormalities in laboratory data. In patients with suspected complications, diagnostic imaging, including computed tomography (CT), was performed as needed. Adverse events and severity grading were defined according a report from a workshop held by the American Society for Gastrointestinal Endoscopy (ASGE) \[[@CR17]\]. Acute pancreatitis was defined as upper abdominal pain associated with nausea or vomiting and accompanied by at least a three-fold elevation of serum amylase or lipase. Significant gastrointestinal bleeding was defined as a drop in the hemoglobin level by \>2 g/dl as compared with the pre-procedure baseline levels together with clinical evidence of bleeding. Abdominal pain was defined as pain not caused by pancreatitis or perforation. Because all EUS-FNA procedures were performed in the hospitalized, the period until oral intake was used as a basis for evaluating severity instead of the length of hospital stay. Severity was classified as mild, moderate, or severe if the patient required less than 3 days of fasting, 4--10 days of fasting, or more than 10 days of fasting, respectively.

Statistical Analysis {#Sec6}
--------------------

Differences and linear trends in the proportions of the categorical variables were analyzed using Fisher's exact test or the Chi square (*χ*^2^) test for trend. Student's *t* test was used to compare continuous variables. Multivariate analysis using a logistic regression model was performed using the forward method. The odds ratios (ORs) and 95 % confidence intervals (95 % CI) were calculated to evaluate the predictors of complications. Two-tailed *P* values of less than 0.05 were considered statistically significant.

Results {#Sec7}
=======

Adverse Events and Severity Grading After EUS-FNA {#Sec8}
-------------------------------------------------

Needle passes were performed for a mean of 2.78 times using 19-, 22-, and 25-G needles for 31 (9.5 %), 268 (82.0 %), and 28 (8.6 %) procedures, respectively (Table [1](#Tab1){ref-type="table"}). The needle pass site was the stomach in 198 cases (60.6 %) and the duodenum in 129 cases (39.4 %). The incidence of adverse events was 3.4 % (11 patients): pancreatitis was noted in 6 patients (moderate in 1 case and mild in 5 cases); mild abdominal pain in 4 patients; and mild bleeding in 1 patient (Table [2](#Tab2){ref-type="table"}). The underlying disease was pancreatic cancer in 7 cases, pancreatic neuroendocrine tumor (PNET) in 3 cases, and chronic pancreatitis in 1 case. Eight cases (73 %) involved small lesions, less than or equal to 20 mm in diameter. A 19-G needle was used in 2 cases, and a 22-G needle was used in the other 9 cases. Needle passes were performed 2 times in 2 cases, 3 times in 4 cases, 4 times in 3 cases, and 5 times in 2 cases. In 9 cases (82 %), the number of needle passes was 3 or more. The needle pass site was the via normal pancreas in 8 cases (73 %) (Table [3](#Tab3){ref-type="table"}). All cases were managed by conservative therapy only.Table 2Incidence of post-procedure events after EUS-FNANo of cases, %Severity gradingPancreatitis6, 1.8Moderate 1, mild 5Abdominal pain4, 1.2Mild 4Bleeding1, 0.3Mild 1Total11, 3.4Moderate 1, mild 10Table 3Characteristics in case of adverse eventsNo.AgeSexDiagnosisLocationSize (mm)Site of needle passNeedle size (gauge)No. of passesPresence or absence of normal pancreasLength of the needle penetrationAdverse eventsSeverity164FPCHead20Duodenum222Presence1--2 cmPancreatitisModerate260MPNETTail26Stomach194AbsencePancreatitisMild383FPCHead18Duodenum223Presence1--2 cmPancreatitisMild478FPNETTail8Stomach224AbsencePancreatitisMild561MPCHead32Duodenum222Presence\<1 cmPancreatitisMild671MPCHead20Duodenum225Presence1--2 cmPancreatitisMild779FPCTail54Stomach224Presence\<1 cmBleedingMild867MPCHead15Duodenum223AbsenceAbdominal painMild975MCPTail5Stomach223Presence\>2 cmAbdominal painMild1058FPCHead15Duodenum193Presence\<1 cmAbdominal painMild1185MPNETHead15Duodenum225Presence\<1 cmAbdominal painMild*PC* pancreatic cancer, *PNET* pancreas neuroendocrine tumor, *CP* chronic pancreatitis

Risk Factors for Adverse Events {#Sec9}
-------------------------------

The following variables were examined in the 327 patients who underwent FNA of the pancreas: age, sex, location of target, tumor size, tumor type (benign, PNET, or other pancreatic tumor), site of needle pass, size of the needle used, mean number of needle passes, whether or not the needle pass was via the normal pancreas, and length of needle penetration into normal pancreas tissue. The results of univariate analysis showed that the incidence of procedural complications was significantly increased in cases involving tumors measuring ≤20 mm in diameter (*P* \< 0.001), cases of PNETS (*P* = 0.012), and cases with an increased length of needle penetration (those in which the puncture needle had to traverse normal pancreas tissue) (*P* = 0.048). Because statistical significance was observed among the 3 disease categories (benign, PNET, and other tumors), we performed paired comparisons. The *P* values for the paired comparisons were as follows: *P* = 0.065 for benign versus PNET, *P* = 1.000 for benign versus other tumors, and *P* = 0.009 for PNET versus other tumors (Table [4](#Tab4){ref-type="table"}). Multivariate analysis identified tumors measuring less than or equal to 20 mm in diameter (OR 18.48; 95 % CI 3.55--96.17) and PNETs (OR 36.50; 95 % CI 1.73--771.83) as independent risk factors (Table [5](#Tab5){ref-type="table"}).Table 4Analysis of risk factors for the complications in patients who underwent FNA of the pancreasWith complicationsWithout complications*P* value^a^*n* = 11*n* = 316Age71.0 ± 9.666.1 ± 11.40.163^b^*Sex*M:F7:4171:1450.760*Location*Head61290.371Body/tail5187*Tumor size (mm)*≤20\
\>203\
8268\
48\<0.001Benign1340.012^c^PNETs311Other tumors (PK, sarcoma, SPN)7271*Site of needle pass*Stomach51930.353Duodenum6123*Needle size (gauge)*250280.263^d^22925919229*Number of needle passes*\<2\
\>32\
9156\
1600.063*Needle pass via the normal pancreas*Yes81430.121No3173*Length of the needle penetration*Absence31730.048^d^\<1 cm4891--2 cm343\>2 cm111^a^Fisher's exact test^b^*t* test^c^*P* values for paired comparisons are as follows: *P* = 0.065 for benign versus PNETs, *P* = 1.000 for benign versus other tumor, and *P* = 0.009 for PNETs versus tumor^d^Chi-square test for trendTable 5Results of logistic regression on complications after EUS-FNA with regard to variablesFactorOR (95 % CI)*P* valueSex (M)1.87 (0.40--8.70)0.424Age1.07 (0.99--1.16)0.088Tumor location (body/tail)0.71 (0.02--21.35)0.845Tumor size (≦20 mm)18.48 (3.55--96.17)\<0.001BenignRef. PNETs36.50 (1.73--771.83)0.021 Other tumor6.76 (0.47--96.38)0.159 Site of needle pass (Duodenum)1.77 (0.06--53.06)0.742 Needle size (22/25-gauge)0.20 (0.03--1.63)0.134 Number of needle passes (\>3 time3.56 (0.56--22.50)0.178Length of the needle penetration AbsenceRef. \<1 cm1.49 (0.24--9.43)0.669 1--2 cm3.20 (0.44--23.02)0.249 \<2 cm9.71 (0.63--148.57)0.103

Discussion {#Sec10}
==========

In this study, the incidence of post-procedural adverse events was 3.4 %, which is slightly higher than that reported in previous studies. However, a prospective study conducted by Sendino et al. \[[@CR18]\] reported a complication rate of 3.1 % and a severe complication rate of 1.2 % in 219 patients undergoing EUS-FNA. Although our study was retrospective, a certain level of accuracy was ensured because the patients undergoing FNA were registered in a database and were admitted to the hospital for the procedure. Additionally, the clinical findings, including the results of blood tests performed on the day after EUS-FNA, were recorded precisely. Furthermore, we were able to properly assess not only the patients with severe complications but also those who experienced mild adverse events. Of these 11 cases, all except 1 experienced mild adverse events. Thus, EUS-FNA appears to be a safe procedure for patients with pancreatic solid lesions.

The relationship between the incidence of adverse events after EUS-FNA and needle size is an important issue, and a 22-G needle was our first choice. Siddiqui et al. \[[@CR19]\] reported that no adverse events were observed after the procedure using either 22- or 25-G needles. In this study, the results of both univariate and multivariate analyses suggested that needle size was not a factor that was significantly associated with an elevated risk of adverse events. In theory, the incidence of adverse events after EUS-FNA with a larger diameter needle was expected to be higher than that after procedures using needles that were smaller in diameter. Needle pass with a larger diameter needle may increase the risk of both tissue damage and adverse events. However, in our study, moderate pancreatitis occurred in 1 patient with pancreatic cancer when we used a 22-G needle and a needle pass in the duodenum (Fig. [2](#Fig2){ref-type="fig"}a). After EUS-FNA, the patient experienced abdominal pain. Abdominal CT revealed fluid collection around the pancreas head (Fig. [2](#Fig2){ref-type="fig"}b). We performed a surgery to remove the pancreatic cancer 19 days after EUS-FNA. The intraoperative findings revealed a blood clot around the pancreas head lesion, and adhesion was confirmed between the pancreas head and the duodenal wall (Fig. [2](#Fig2){ref-type="fig"}c). However, the resection was completely successful.Fig. 2A case of pancreatitis after EUS-FNA. **a** FNA was performed using 22-gauge needle. **b** Abdominal CT revealed fluid collection around the pancreas head. **c** The intraoperative findings revealed a blood clot around the pancreas head lesion, and adhesion was confirmed between the pancreas head and the duodenal wall

In this study, univariate analysis revealed the following statistically significant risk factors for post procedural adverse events: tumors measuring less than or equal to 20 mm in diameter, 3 or more punctures, and a greater length of penetration in cases where the needle pass had to traverse normal pancreas tissue. Furthermore, in our multivariate analysis, small tumor size and PNETs were found to be significant independent risk factors. One of the potential causes of adverse events may be the difficulty in performing needle passes for small lesions. Needle passes for small tumors may be more difficult to execute than those for large tumor masses. Occasionally, many needle passes are required because the target is too small. In addition, back-and-forth movement is difficult. This may lead to pancreatic damage and adverse effects such as pancreatitis and bleeding. Moreover, the possible causes of pancreatitis include injuries to the main pancreatic duct or its branches. Although penetration through the normal pancreas was not found to be a risk factor in our multivariate analysis, a needle pass through the normal pancreas was more likely to be necessary for accessing small lesions, and the possibility of injuries to the normal pancreas and the main pancreatic duct or its branches cannot be ignored. Vascularity of the target lesion is another factor. Our data demonstrate that PNETs are a risk factor for adverse events. In general, PNETs are hypervascular tumors and the risk of bleeding from these tumors is increased compared with other tumors. When bleeding occurs around the pancreatic parenchyma after EUS-FNA, it may cause inflammation and lead to adverse events. These factors may have helped identify a small tumor size and PNETs as risk factors. Because this was a retrospective study, a prospective study involving a larger number of patients is needed to precisely determine the risk of adverse events.

The limitations of this study included the fact that it was a retrospective analysis performed at a single center, and only pancreatic solid lesions were included. Cystic lesions of the pancreas, especially intraductal papillary neoplasms (IPMN), are contraindications for EUS-FNA not only in our center but also in many other Japanese institutions because of the risk of tumor dissemination due to leakage of cystic fluid. For this reason, we could only evaluate pancreatic solid lesions. The frequency of complications associated with pancreatic solid lesions after EUS-FNA is low compared with that associated with cystic lesions \[[@CR12], [@CR20]\]. However, in our study, the rate of complications was 3.4 %, including mild cases. The possible mechanisms for the development of adverse events differ depending on whether the lesion is solid or cystic. Therefore, determining the risk factors for adverse events after EUS-FNA in patients with pancreatic solid lesions is very important. Moreover, owing to improvements in echoendoscope and needles, we can now visualize smaller lesions and attempt to perform EUS-FNA of these lesions. For these reasons, a clarification of the risk factors associated with EUS-FNA is necessary.

In conclusion, EUS-FNA of pancreatic solid lesions is a safe procedure. However, pancreatic lesions with small diameters and PNETs are important factors associated with adverse events following EUS-FNA.

None.
